On Monday, Following U.S. Stocks were among the “Top Gainers”: Coeur Mining, Inc. (NYSE:CDE), Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), Juno Therapeutics Inc. (NASDAQ:JUNO), Amgen Inc. (NASDAQ:AMGN)
Coeur Mining, Inc. (NYSE:CDE), with shares inclined 6.32%, closed at $5.05.
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX), with shares jumped 6.22%, settled at $4.44, hitting new 52-week high of $4.53.
Juno Therapeutics Inc. (NASDAQ:JUNO), with shares climbed 6.06%, and closed at $52.49.
Amgen Inc. (NASDAQ:AMGN), surged 5.69%, and closed at $163.03.
Latest NEWS regarding these Stocks are depicted underneath:
Coeur Mining, Inc. (NYSE:CDE)
Coeur Mining, Inc. (CDE)’s President, Chief Executive Officer, and Director, Mitchell J. Krebs, presented at the ROTH Conference in Dana Point, California on March 9, 2015.
Highlights of Mr. Krebs’s presentation comprise:
- An overview of Coeur’s planned priorities and three-year outlook,
- Coeur’s recent financial performance and achievements,
- Recently accomplished attainment of the Wharf mine and formerly declared attainment of Paramount Gold and Silver Corp.
Coeur Mining is the largest U.S.-based primary silver producer and a noteworthy gold producer with five precious metals mines in the Americas employing about 2,100 people. Coeur produces from its wholly owned operations: the Palmarejo silver-gold mine in Mexico, the San Bartolome silver mine in Bolivia, the Rochester silver-gold mine in Nevada, the Kensington gold mine in Alaska, and the Wharf gold mine in South Dakota.
Catalyst Pharmaceutical Partners Inc. (NASDAQ:CPRX)
Catalyst Pharmaceutical Partners Inc. (CPRX), a biopharmaceutical corporation focused on developing and commercializing innovative therapies for people with rare debilitating diseases, stated financial results for the fourth quarter and year-ended December 31, 2014.
2014 and Recent Highlights:
- Positive top-line results from the pivotal Phase 3 clinical trial of Firdapse(TM) for the symptomatic treatment of Lambert-Eaton myasthenic syndrome (LEMS).
- David D. Muth promoted to Chief Commercial Officer to develop and execute the Corporation’s planned plan, counting planning for the commercial launch of Firdapse(TM).
- Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by treating patients with CPP-115, covers CPP-115 for neurological and psychological uses until 2032.
- Raised $34.7 million, net of expenses, in a public offering of shares of ordinary stock during February 2015, resulting in pro-forma cash and investments as of December 31, 2014 of about $74 million.
- Orphan drug designation granted for Firdapse(TM) by the FDA for treatment of patients with Congenital Myasthenic Syndromes (CMS).
- Encouraging Pre-NDA meeting with the FDA conducted.
- Launched our Firdapse(TM) Expanded Access Program. Catalyst is presently enrolling physicians treating LEMS and CMS patients in the expanded access program, which will provide Firdapse(TM) at no charge to their patients who meet the inclusion/exclusion requirements.
Catalyst Pharmaceuticals is a biopharmaceutical corporation focused on developing and commercializing innovative therapies for people with rare debilitating diseases, counting Lambert-Eaton Myasthenic Syndrome (LEMS), congenital myasthenic syndrome (CMS), infantile spasms, and Tourette Syndrome.
Juno Therapeutics Inc. (NASDAQ:JUNO)
Juno Therapeutics Inc. (JUNO), will declare financial results for the fourth quarter and year ended December 31, 2014 on Wednesday, March 18, 2015 after the close of U.S.-based financial markets. Hans E. Bishop, President and Chief Executive Officer, and Steven D. Harr, Chief Financial Officer, will host a conference call to review the results starting at 2:00 p.m. Pacific Time (PT)/5:00 p.m. Eastern Time (ET).
Juno Therapeutics, Inc. is building a fully integrated biopharmaceutical corporation focused on revolutionizing medicine by re-engaging the body’s immune system to treat cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer.
Amgen Inc. (NASDAQ:AMGN)
Amgen Inc. (AMGN), declared one-year data from prespecified exploratory endpoints of adjudicated cardiovascular events in the Phase 2 (OSLER-1) and Phase 3 (OSLER-2) open-label extension studies of Repatha™ (evolocumab), a novel investigational low-density lipoprotein cholesterol (LDL-C)-lowering medication. These data were presented recently at a Late-Breaking Clinical Trial session at the American College of Cardiology’s 64th Annual Scientific Session (ACC.15) and published in the New England Journal of Medicine. A two-year analysis of Repatha safety and tolerability data from the longest proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor trial to date (OSLER-1) was also presented.
Data from prespecified exploratory endpoints in the ongoing open-label OSLER-1 and OSLER-2 studies showed Repatha plus standard of care (SOC) treatment reduced adjudicated cardiovascular events (0.95 percent Repatha plus SOC; 2.18 percent SOC) over a one-year analysis period. Adverse events (AEs) (≥1 percent in the Repatha plus SOC group and more frequent in the Repatha plus SOC group by at least 1 percent) comprised of arthralgia, headache, pain in extremity and fatigue. The cardiovascular events analysis comprises exploratory findings from the ongoing open-label OSLER studies. Repatha plus SOC treatment reduced LDL-C by 61 percent contrast to SOC.
“We are excited to present several data analyses at ACC.15 from the Repatha clinical trial program, counting an analysis of cardiovascular events and safety data from the longest PCSK9 inhibitor trial to date,” said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. “The clinical data are encouraging, and we look forward to seeing the results from our cardiovascular outcomes trial, FOURIER, which was designed to investigate whether there is a substantial reduction in the occurrence of major cardiovascular events with the use of Repatha. We continue to work with regulatory agencies to make Repatha accessible to patients.”
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach starts by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
